Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$6.25 USD
-0.07 (-1.11%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.26 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Voyager Therapeutics, Inc. [VYGR]
Reports for Purchase
Showing records 1 - 20 ( 152 total )
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
TRACER Keeps On Giving -- New NVS License Agreement Brings In $15M Upfront
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Anti-Tau Antibody Program Advancing in Phase 1; Three Gene Therapy INDs Expected in 2025; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Neuro Perspectives Conference Takeaways: Investable Opportunities in Mental Health and Neurological Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Results; Anti-Tau Antibody Program Cleared for Phase 1 Trial; Gene Therapy Pipeline Progressing on Track; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Tracking Tau -- Looking Ahead To Clinical Advancement
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Raise When You Can -- VYGR Announces Secondary Offering
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
New NVS Agreement Generates More Non-Dilutive Capital To Start Year
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Optimized Entry and Exit Levels for VYGR 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Tau Efforts Continue To Tick Closer To Clinic; All Efforts On Track
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
All Cylinders Firing With SOD1 Candidate Selection Nearing
Provider: Wedbush Securities Inc.
Analyst: CHICO L